We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sotatercept

News List

Acceleron gets EC orphan designation for sotatercept to treat PAH pharmaceutical-business-review
December 17, 2020
Acceleron Pharma has secured orphan designation from the European Commission (EC) for its sotatercept to treat patients with pulmonary arterial hypertension (PAH).
Acceleron receives PRIME designation from EMA for Sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
May 06, 2020
Acceleron Pharma said that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
April 14, 2020
Acceleron Pharma announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
FDA grants Orphan Drug Designation to sotatercept europeanpharmaceuticalreview
September 16, 2019
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.